Pasiniazid - CAS 2066-89-9
Category:
APIs
Product Name:
Pasiniazid
Catalog Number:
2066-89-9
Synonyms:
4-amino-2-hydroxybenzoic acid;pyridine-4-carbohydrazide Fintosid isoniazide 4-aminosalicylate pasiniazide
CAS Number:
2066-89-9
Description:
Pasiniazid, aslo alled as Fintosid, can be used to treat pulmonary tuberculosis (MDR-TB) and leprosy.
Molecular Weight:
290.28
Molecular Formula:
C13H14N4O4
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
C1=CC(=C(C=C1N)O)C(=O)O.C1=CN=CC=C1C(=O)NN
InChI:
1S/C7H7NO3.C6H7N3O/c8-4-1-2-5(7(10)11)6(9)3-4;7-9-6(10)5-1-3-8-4-2-5/h1-3,9H,8H2,(H,10,11);1-4H,7H2,(H,9,10)
InChIKey:
RKPHTRVPGYGVQD-UHFFFAOYSA-N
Chemical Structure
CAS 2066-89-9 Pasiniazid

Reference Reading


1.Safety and tolerability profile of second-line anti-tuberculosis medications.
Ramachandran G1, Swaminathan S. Drug Saf. 2015 Mar;38(3):253-69. doi: 10.1007/s40264-015-0267-y.
Tuberculosis (TB) remains a major public health problem, representing the second leading cause of death from infectious diseases globally, despite being nearly 100 % curable. Multidrug-resistant (MDR)-TB, a form of TB resistant to isoniazid and rifampicin (rifampin), two of the key first-line TB drugs, is becoming increasingly common. MDR-TB is treated with a combination of drugs that are less effective but more toxic than isoniazid and rifampicin. These drugs include fluoroquinolones, aminoglycosides, ethionamide, cycloserine, aminosalicyclic acid, linezolid and clofazimine among others. Minor adverse effects are quite common and they can be easily managed with symptomatic treatment. However, some adverse effects can be life-threatening, e.g. nephrotoxicity due to aminoglycosides, cardiotoxicity due to fluoroquinolones, gastrointestinal toxicity due to ethionamide or para-aminosalicylic acid, central nervous system toxicity due to cycloserine, etc.
2.Sensititre® MYCOTB MIC plate for drug susceptibility testing of Mycobacterium tuberculosis complex isolates.
Yu X1, Ma YF1, Jiang GL1, Chen ST1, Wang GR1, Huang HR2. Int J Tuberc Lung Dis. 2016 Mar;20(3):329-34. doi: 10.5588/ijtld.15.0573.
SETTING: National Tuberculosis Clinical Laboratory, China.
3.Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry.
Kim HJ1, Seo KA1, Kim HM1, Jeong ES1, Ghim JL1, Lee SH2, Lee YM3, Kim DH4, Shin JG5. J Pharm Biomed Anal. 2015 Jan;102:9-16. doi: 10.1016/j.jpba.2014.08.026. Epub 2014 Sep 1.
A simple and accurate liquid chromatography (LC)-tandem mass spectrometry (MS/MS) method for the quantitation of 20 anti-tuberculosis (anti-TB) drugs in human plasma, was developed as a tool for therapeutic drug monitoring. Two protein precipitation methods were adopted; one using methanol containing 0.13N HCl, for precipitation of amikacin, kanamycin, streptomycin and pyrazinamide, and the other using acetonitrile, for precipitation of preamoxicillin, ciprofloxacin, clarithromycin, clofazimine, cycloserine, ethambutol, ethionamide, isoniazid, levofloxacin, linezolid, moxifloxacin, p-aminosalicylic acid (PAS), prothionamide, rifabutin, rifampin and roxithromycin. Separation was performed either on an HILIC silica column or a reversed-phase dC18 column, with a gradient elution. Detection was carried out in multiple reaction-monitoring (MRM) mode. The calibration curves were linear over a 50-fold concentration range, with correlation coefficients (r) greater than 0.
4.Mycobacterial Interspersed Repetitive Unit Can Predict Drug Resistance of Mycobacterium tuberculosis in China.
Cheng XF1, Jiang C2, Zhang M3, Xia D2, Chu LL4, Wen YF2, Zhu M5, Jiang YG6. Front Microbiol. 2016 Mar 23;7:378. doi: 10.3389/fmicb.2016.00378. eCollection 2016.
BACKGROUND: Recently, Mycobacterial Interspersed Repetitive Unit (MIRU) was supposed to be associated with drug resistance in Mycobacterium tuberculosis (M. tuberculosis), but whether the association exists actually in local strains in China was still unknown. This research was conducted to explore that association and the predictability of MIRU to drug resistance of Tuberculosis (TB).